Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Mesothelioma

A. Moore, R. Parker, J. Wiggins
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis. The exact prevalence is unknown but it is estimated that mesotheliomas represent less than 1% of all cancers. Its incidence is increasing, with an expected peak in the next 10–20 years. Pleural malignant mesothelioma is the most common form of mesothelioma. Typical presenting features are those of chest pain and dyspnoea. Breathlessness due to a pleural effusion without chest pain is reported in about 30% of patients. A chest wall mass, weight loss, sweating, abdominal pain and ascites (due to peritoneal involvement) are less common presentations. Mesothelioma is directly attributable to occupational asbestos exposure with a history of exposure in over 90% of cases. There is also evidence that mesothelioma may result from both para-occupational exposure and non-occupational "environmental" exposure. Idiopathic or spontaneous mesothelioma can also occur in the absence of any exposure to asbestos, with a spontaneous rate in humans of around one per million. A combination of accurate exposure history, along with examination radiology and pathology are essential to make the diagnosis. Distinguishing malignant from benign pleural disease can be challenging. The most helpful CT findings suggesting malignant pleural disease are 1) a circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of > 1 cm and 4) mediastinal pleural involvement. Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care. Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
This paper references
Orphanet Journal of Rare Diseases
Orphanet (2019)
10.1097/00000421-199002000-00002
The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy
D. Ball (1990)
10.1016/j.athoracsur.2007.11.039
Management of malignant pleural effusions using the Pleur(x) catheter.
W. Warren (2008)
10.1002/14651858.CD002916.PUB2
Pleurodesis for malignant pleural effusions.
P. Shaw (2004)
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.
J. Testa (1998)
10.1093/OCCMED/KQI034
Mesothelioma mortality in Great Britain from 1968 to 2001.
D. McElvenny (2005)
Improving quality of life in patients with malignant pleural mesothelioma: results of the randomised pemetrexed + cisplatin trial using the LCSS-meso instrument (abstract)
R Gralla (2003)
10.1023/A:1008236010868
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
George W. Middleton (1998)
10.1136/thx.52.2008.S52
Asbestos, Simian virus 40 and malignant mesothelioma
S. Stenton (1997)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
10.1093/OCCMED/KQM079
Simian virus 40 and mesothelioma in Great Britain.
M. Price (2007)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1093/OXFORDJOURNALS.QJMED.A067473
The clinical aspects of mesothelioma.
P. Elmes (1976)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1111/J.1440-1673.1994.TB00177.X
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
S. Davis (1994)
10.1158/0008-5472.CAN-04-2461
Evidence against a role for SV40 in human mesothelioma.
J. Manfredi (2005)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1538/EXPANIM.56.155
Spontaneous peritoneal malignant mesothelioma in a geriatric japanese macaque (Macaca fuscata).
J. Yamate (2007)
The pathogenesis of mesotheli
M Carbone (2006)
Malignant Pleural Mesothelioma. Clinical Respiratory Medicine. Mosby 2nd edition
J Jett
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.1179/oeh.2004.10.1.26
Malignant Pleural Mesothelioma—An Update
D. Stewart (2004)
10.1016/J.LUNGCAN.2007.09.027
Current state and future directions of pleural mesothelioma imaging.
S. Armato (2008)
10.2214/AJR.154.3.2106209
CT in differential diagnosis of diffuse pleural disease.
A. Leung (1990)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0936-6555(05)80540-0
Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy.
E. Low (1995)
Evidence against a role for SV 40 in human mesothe
JJ Manfredi (2005)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma
A Scherpereel (2006)
10.1093/OCCMED/KQI034
Mesothelioma mortality in Great Britain from 1968 to 2001.
D. McElvenny (2005)
10.1016/J.CLINIMAG.2005.12.027
Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos.
F. Okten (2006)
10.1016/J.YRTPH.2007.10.003
Mesothelioma and asbestos.
G. Gibbs (2008)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1538/EXPANIM.56.155
Spontaneous peritoneal malignant mesothelioma in a geriatric japanese macaque (Macaca fuscata).
J. Yamate (2007)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
abolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
F Benard (1998)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
Improving quality of life in patients with malignant pleural mesothelioma: results of the randomised pemetrexed + cisplatin trial using the LCSS-meso instrument (abstract)
R Gralla (2003)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1053/J.SEMDP.2006.08.002
The pathogenesis of mesothelioma.
M. Carbone (2006)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1093/OXFORDJOURNALS.QJMED.A067473
The clinical aspects of mesothelioma.
P. Elmes (1976)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1136/thx.52.2008.S52
Asbestos, Simian virus 40 and malignant mesothelioma
S. Stenton (1997)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.1002/14651858.CD003880.PUB4
Radiotherapy for malignant pleural mesothelioma.
E. Chapman (2006)
10.1080/17843286.1989.11718015
Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma.
D. Selleslag (1989)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1982)
10.1053/J.SEMDP.2006.08.002
The pathogenesis of mesothelioma.
M. Carbone (2006)
10.1510/ICVTS.2005.123430
The MARS trial: mesothelioma and radical surgery.
T. Treasure (2006)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1136/THORAX.58.SUPPL_2.II29
BTS guidelines for the management of malignant pleural effusions.
G. Antunes (2003)
10.1016/J.LUNGCAN.2005.03.030
CT, RECIST, and malignant pleural mesothelioma.
A. Nowak (2005)
BTS statement on malignant mesothelioma
J Wiggins (2007)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
Curr Opin Pulm Med
Md Zervos (2008)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/S1010-7940(00)00422-X
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
O. Genc (2000)
10.1158/0008-5472.CAN-04-2461
Evidence against a role for SV40 in human mesothelioma.
J. Manfredi (2005)
10.1183/09031936.00079407
Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource
R. Muirhead (2007)
10.1183/09031936.96.09061206
Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic?
K. Sakellariou (1996)
10.1080/17843286.1989.11718015
Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma.
D. Selleslag (1989)
10.1016/S1092-9134(03)00078-9
Current controversies regarding the role of asbestos exposure in the causation of malignant mesothelioma: the need for an evidence-based approach to develop medicolegal guidelines.
A. Marchevsky (2003)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1016/S0954-6111(98)90519-4
Finger clubbing in malignant mesothelioma and benign asbestos pleural disease.
C. Mcgavin (1998)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1136/oem.56.1.51
Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.
D. Howel (1999)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1136/thorax.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1097/MCP.0b013e328302851d
Malignant mesothelioma 2008
M. Zervos (2008)
10.1183/09031936.96.09061206
Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic?
K. Sakellariou (1996)
10.1097/00004728-199505000-00006
CT‐Guided Pleural Needle Biopsy in the Diagnosis of Malignant Mesothelioma
M. Metintas (1995)
10.1177/0004563217741145
Biomarkers in mesothelioma
D. Arnold (2018)
10.1378/CHEST.125.2.489
Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
B. Duysinx (2004)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Ann Oncol
(2007)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/0360-3016(91)90054-8
Deterioration in lung function following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.1186/1750-1172-1-44
Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40
K. Leithner (2006)
10.1016/J.LUNGCAN.2007.09.027
Current state and future directions of pleural mesothelioma imaging.
S. Armato (2008)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1016/S0140-6736(04)17102-X
Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids
F. Lopez-Rios (2004)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1016/J.CLINIMAG.2005.12.027
Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos.
F. Okten (2006)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
MESO- MARK: a potential test for malignant pleural mesothelioma
Hl Beyer (2007)
10.1016/S0140-6736(04)17102-X
Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids
F. Lopez-Rios (2004)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1179/oeh.2004.10.1.26
Malignant Pleural Mesothelioma—An Update
D. Stewart (2004)
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.
J. Testa (1998)
10.4065/83.2.235
Recent advances in the diagnosis and management of malignant pleural effusions.
J. Heffner (2008)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1023/A:1008236010868
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
George W. Middleton (1998)
10.1183/09031936.00079407
Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource
R. Muirhead (2007)
Pastan I: Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of othelioma: clinical implementation
M Onda (2003)
10.1183/2312508x.erm6815
Lung cancer.
H. Hansen (1990)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1097/00004728-199505000-00006
CT‐Guided Pleural Needle Biopsy in the Diagnosis of Malignant Mesothelioma
M. Metintas (1995)
10.1378/CHEST.125.2.489
Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
B. Duysinx (2004)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
10.1016/S0936-6555(05)80540-0
Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy.
E. Low (1995)
10.2214/AJR.154.3.2106209
CT in differential diagnosis of diffuse pleural disease.
A. Leung (1990)
Exp. Anim
Tianlong Liu (2019)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1148/RADIOLOGY.210.1.R99DC04277
Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis.
E. Marom (1999)
10.1164/RCCM.200311-1579OC
Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size.
N. Maskell (2004)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Mesothelioma mortality in Great Britain
DM McElvenny (1968)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1016/S0378-4274(01)00507-0
Lung diseases due to environmental exposures to erionite and asbestos in Turkey.
S. Emri (2002)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1136/thorax.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1016/0360-3016(91)90054-8
Deterioration in lung function following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1016/S1092-9134(03)00078-9
Current controversies regarding the role of asbestos exposure in the causation of malignant mesothelioma: the need for an evidence-based approach to develop medicolegal guidelines.
A. Marchevsky (2003)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1016/J.YRTPH.2007.10.003
Mesothelioma and asbestos.
G. Gibbs (2008)
Current state and future directions of pleural mesothelioma imaging
SG 3rdArmato (2008)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
10.1016/J.EJCTS.2005.10.008
Multimodality approach in management of malignant pleural mesothelioma.
S. Neragi-Miandoab (2006)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1016/S0936-6555(05)80582-5
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
10.1093/OCCMED/KQM079
Simian virus 40 and mesothelioma in Great Britain.
M. Price (2007)
Herndon JE: Malignant pleural effusions: treatment with smallbore-catheter thoracostomy and talc pleurodesis
E M Marom (1999)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1016/S0954-6111(98)90519-4
Finger clubbing in malignant mesothelioma and benign asbestos pleural disease.
C. Mcgavin (1998)
10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
10.1510/ICVTS.2005.123430
The MARS trial: mesothelioma and radical surgery.
T. Treasure (2006)
10.1186/1750-1172-1-44
Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40
K. Leithner (2006)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1016/S0378-4274(01)00507-0
Lung diseases due to environmental exposures to erionite and asbestos in Turkey.
S. Emri (2002)
10.1016/J.CLON.2006.12.006
The role of radiotherapy in the treatment of malignant pleural mesothelioma.
K. Waite (2007)
10.1136/oem.56.1.51
Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.
D. Howel (1999)
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of Page 9 of 11 (page number not for citation purposes) Orphanet Journal of Rare Diseases
M Onda (2006)
Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma
A Scherpereel (2006)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)



This paper is referenced by
Immunotherapy advances for mesothelioma
Emyr Bakker (2018)
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
Matthew Wu (2015)
Mesothelioma incidence and mortality in South Africa from 2003 to 2013
Kasongo Michel Muteba (2018)
10.1177/030089161009600504
No Implication of Simian virus 40 in pathogenesis of Malignant Pleural Mesothelioma in Slovenia
J. Hmeljak (2010)
Mesothelioma in South Africa 3 decades post peak of asbestos production an analysis of a claims database of asbestos ex-miners
Mokgadi Mothemela (2012)
MALİGN PLEVRAL EFFÜZYONLARIN TANISINDA SİTOPATOLOJİ
K. Bakır (2009)
10.1007/s00384-014-2029-1
Advances in malignant peritoneal mesothelioma
Shoubo Cao (2014)
10.1007/s12253-013-9677-2
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
10.1038/modpathol.2009.180
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
10.7314/APJCP.2012.13.11.5735
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years' experience in Turkey.
S. Berk (2012)
10.2147/NRR.S44751
Pleural mesothelioma: management updates and nursing initiatives to improve patient care
Rebecca H Lehto (2014)
Dysphagia in solid malignancies outside the head, neck and upper gastrointestinal tract
Ciarán Kenny (2019)
10.21608/EJOM.2019.31415
ENVIRONMENTAL AND OCCUPATIONAL RISK FACTORS AND PREDICTORS OF SURVIVAL AMONG MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
A. Abdel-HamidM (2019)
Ventilatory mechanics in thoracic surgery
G. A. Elshafie (2017)
10.1007/s00432-011-1030-0
BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients
J. Hmeljak (2011)
10.5798/diclemedj.0921.2013.01.0214
Peritoneal mesothelioma: Contribution of computerized tomography and magnetic resonance imaging findings to differential diagnosis Peritoneal mezotelyoma: Bilgisayarli tomografi ve magnetik rezonans görüntüleme bulgularinin ayirici taniya katkisi
N. Arda (2013)
10.1111/j.1462-2920.2010.02337.x
Streptomyces associated with a marine sponge Haliclona sp.; biosynthetic genes for secondary metabolites and products.
S. Khan (2011)
5 Testicular Mesothelioma
Alexander N. Zubritsky (2012)
10.1038/nrrheum.2009.216
Meticillin-sensitive Staphylococcus aureus costochondritis in a healthy man
A. Mohammad (2009)
10.1007/s11605-014-2664-4
Predictive Factors Analysis for Malignant Peritoneal Mesothelioma
S. Jin (2014)
10.1007/s00059-016-4522-5
Malignant pericardial mesothelioma
S. Cao (2016)
Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic.
E. Skammeritz (2011)
10.1016/j.yrtph.2012.05.015
Malignant pleural mesothelioma in US automotive mechanics: reported vs expected number of cases from 1975 to 2007.
B. Finley (2012)
10.1093/icvts/ivt465
Advanced malignant mesothelioma mimicking acute contained thoracic aortic rupture.
Nicolas J. Mouawad (2014)
10.1007/s10653-013-9518-y
The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey
S. Berk (2013)
10.1016/J.MEDIPA.2014.11.001
Mesotelioma pleural maligno
Eva María García Atienza (2017)
10.1097/pdm.0b013e3182a3645e
Low Frequency of EGFR Mutations in Pleural Mesothelioma Patients, Cologne, Germany.
V. Schildgen (2014)
10.1007/s00428-013-1373-9
Is survivin expression prognostic or predictive in malignant pleural mesothelioma?
J. Hmeljak (2013)
10.1007/s00580-011-1177-8
Thoracic and abdominal mesothelioma in a dog: a cytologist’s view
D. Martins (2011)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.4267/2042/55382
Mesothelioma: t(14;22)(q32;q12) in mesothelioma
I. Panagopoulos (2014)
10.1200/JCO.2013.31.15_SUPPL.E18544
Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
M. Kuçukoner (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar